Scholarlink

Background <p>Rare diseases present urgent public health challenges requiring coordinated global efforts. This study analyzes China’s orphan drug innovation landscape through patent applications (1995–2023) to identify R&amp;D patterns and policy implications.</p> Methods <p>We analyzed 323 Patent Cooperation Treaty applications from Chinese entities using IPC classification and bipartite network modeling. Data from World Intellectual Property Organization were retrieved via PatSnap, with diseases mapped to China’s Rare Disease Catalogues (207 conditions). Network metrics quantified disease-technology linkages.</p> Results <p>Three key findings emerged: (1) Patent filings surged 58.2% (188 patents) during 2018–2023, coinciding with China’s regulatory reforms; (2) Innovation concentrated in oncology/neurology (34.3% patents cover 2 diseases), with 66.2% of catalogued diseases lacking patents; (3) Dominant technologies are small molecules and genetic therapies. Network analysis revealed an R&amp;D ecosystem without a single dominant entity, alongside robust collaborative ties between Chinese and U.S. organizations.</p> Conclusions <p>China’s orphan drug innovation is expanding rapidly but remains uneven, concentrated in specific diseases and technological platforms. Policy interventions are needed to address therapeutic neglect through tiered incentives, dedicated funding for neglected diseases, and global partnerships to accelerate equitable treatment access.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Patent Analysis Perspectives on China’s Orphan Drug R&D: Status and Technology Characteristics

  • 期刊论文

  • 发表日期：

    2026年2月16日

查看全文
  • Yang Jiao,
  • Fangzhe Yuan,
  • Tianyu Liu,
  • Jiajia Han,
  • Jingchun Sun,
  • Shuzhen Chu,
  • Shuxiang Li

摘要

Background

Rare diseases present urgent public health challenges requiring coordinated global efforts. This study analyzes China’s orphan drug innovation landscape through patent applications (1995–2023) to identify R&D patterns and policy implications.

Methods

We analyzed 323 Patent Cooperation Treaty applications from Chinese entities using IPC classification and bipartite network modeling. Data from World Intellectual Property Organization were retrieved via PatSnap, with diseases mapped to China’s Rare Disease Catalogues (207 conditions). Network metrics quantified disease-technology linkages.

Results

Three key findings emerged: (1) Patent filings surged 58.2% (188 patents) during 2018–2023, coinciding with China’s regulatory reforms; (2) Innovation concentrated in oncology/neurology (34.3% patents cover 2 diseases), with 66.2% of catalogued diseases lacking patents; (3) Dominant technologies are small molecules and genetic therapies. Network analysis revealed an R&D ecosystem without a single dominant entity, alongside robust collaborative ties between Chinese and U.S. organizations.

Conclusions

China’s orphan drug innovation is expanding rapidly but remains uneven, concentrated in specific diseases and technological platforms. Policy interventions are needed to address therapeutic neglect through tiered incentives, dedicated funding for neglected diseases, and global partnerships to accelerate equitable treatment access.